Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 13/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766071 | 0.81 | MAOA (0.57) | MAOACYP2E1F10F2 | |
| SCHEMBL11969046 | 0.78 | MAOA (0.50) | MAOACYP2E1F10ITGB3ITGA2B | |
| SCHEMBL13428739 | 0.76 | MAOA (0.51) | MAOACYP2E1F10 | |
| SCHEMBL13428748 | 0.74 | MAOA (0.52) | MAOACYP2E1F10F2 | |
| SCHEMBL11969777 | 0.74 | MAOA (0.52) | MAOACYP2E1F10F2 | |
| SCHEMBL11969006 | 0.74 | MAOA (0.54) | MAOACYP2E1F10 | |
| SCHEMBL3323189 | 0.73 | MAOA (0.79) | MAOACYP2E1 | |
| SCHEMBL3323196 | 0.73 | MAOA (0.79) | MAOACYP2E1 | |
| SCHEMBL3323187 | 0.73 | MAOA (0.79) | MAOACYP2E1 | |
| SCHEMBL5833654 | 0.73 | MAOA (0.51) | MAOACYP2E1F10ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036000-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |